ONCO Share Price Performance
SEK 0
-1.49 (-100.00%)
Price SEK 0
Fair ValueSEK 2.80
Share Pricen/a
Narrative Update • Jun 25
Oncopeptides AB (publ) Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
ONCO Community Narratives
AN
Fair Value
·Fair Value SEK 2.8 42.2% undervalued intrinsic discount
EU And Japan Expansion Will Leverage Aging Population Trends
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value SEK 3.1 47.8% undervalued intrinsic discount
Aging Population And Precision Oncology Will Open New Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
DA
Fair Value
·Fair Value SEK 2.56 36.8% undervalued intrinsic discount
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment
0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment
Oncolytics Biotech is pushing a new immune-based cancer treatment that’s showing encouraging early signs in some of the hardest-to-treat cancers, including pancreatic and certain digestive cancers. A recent green light from a German regulator and fresh conference results hint at momentum, but the big question is whether later trial readouts can hold up.Read more
DA
SEK 2.56
36.8% undervalued intrinsic discount
Fair Value
Profit Margin
19.92%
Future PE
27.43x
Price in 2030
SEK 3.44
Aging Population And Precision Oncology Will Open New Markets
Oncopeptides is pushing its cancer drug into more European hospitals faster than many expect, which could bring a step-change in sales if doctors keep seeing good results in older, frailer patients. The big swing factor is whether it can land a Japan partner and avoid setbacks or new rivals, because the business still leans heavily on a single treatment.Read more
AN
SEK 3.1
47.8% undervalued intrinsic discount
Fair Value
Profit Margin
11.71%
Future PE
34.37x
Price in 2029
SEK 3.66
EU And Japan Expansion Will Leverage Aging Population Trends
Key Takeaways Accelerating Pepaxti sales, positive market trends, and strict cost controls position the company for sustainable growth and improving margins. Expansion efforts and pipeline development create multiple paths for future revenue and strategic partnerships.Read more
AN
SEK 2.8
42.2% undervalued intrinsic discount
Fair Value
Profit Margin
22%
Future PE
10.56x
Price in 2029
SEK 3.32
European Pricing And Regulatory Pressures Will Erode Value
Key Takeaways Reliance on a single product and tougher regulatory standards heighten financial and operational risks, risking abrupt drops in sales and delayed growth. Competitive pressures, shrinking pricing power, and constrained funding threaten market share, margin stability, and the company's long-term financial health.Read more
AN
SEK 4.5
64.0% undervalued intrinsic discount
Fair Value
Profit Margin
16.83%
Future PE
21.73x
Price in 2029
SEK 5.27
Trending Discussion
Recently Updated Narratives
DA
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment
Fair Value: SEK 2.56 36.8% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
ONCO: Expanded Multiple Myeloma Indication Will Drive Long-Term Upside
Fair Value: SEK 3.1 47.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ONCO: Rights Issue And Glioblastoma Study Will Support Bullish Long Term View
Fair Value: SEK 2.8 42.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Oncopeptides AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 27, 2026
- -0.56
- 96.57%
- -265.63%
- 170.3%
About ONCO
- Founded
- 2000
- Employees
- 77
- CEO
- WebsiteView website
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
